Q2 2018 EPS Estimates for Opiant Pharmaceuticals Inc Lifted by Analyst (OPNT)

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) – Zacks Investment Research boosted their Q2 2018 earnings estimates for shares of Opiant Pharmaceuticals in a report released on Tuesday. Zacks Investment Research analyst D. Bautz now expects that the technology company will post earnings per share of $4.33 for the quarter, up from their prior estimate of $3.76. Zacks Investment Research also issued estimates for Opiant Pharmaceuticals’ FY2018 earnings at $0.73 EPS.

Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings results on Monday, December 4th. The technology company reported ($2.77) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($1.58). The company had revenue of $0.02 million during the quarter. Opiant Pharmaceuticals had a return on equity of 42.44% and a net margin of 8.93%.

A number of other brokerages also recently weighed in on OPNT. ValuEngine downgraded shares of Opiant Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, October 27th. TheStreet cut Opiant Pharmaceuticals from a “b” rating to a “c+” rating in a research note on Friday, November 24th.

Opiant Pharmaceuticals (NASDAQ:OPNT) opened at $24.86 on Thursday. The firm has a market cap of $51.26, a PE ratio of 59.19 and a beta of -2.85. Opiant Pharmaceuticals has a fifty-two week low of $5.00 and a fifty-two week high of $51.90.

An institutional investor recently bought a new position in Opiant Pharmaceuticals stock. Acadian Asset Management LLC acquired a new stake in Opiant Pharmaceuticals Inc (NASDAQ:OPNT) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 7,577 shares of the technology company’s stock, valued at approximately $174,000. Acadian Asset Management LLC owned 0.37% of Opiant Pharmaceuticals as of its most recent filing with the SEC. 2.16% of the stock is currently owned by institutional investors and hedge funds.

In related news, major shareholder Geoffrey Wolf sold 2,570 shares of the business’s stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $30.40, for a total value of $78,128.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 63.82% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Q2 2018 EPS Estimates for Opiant Pharmaceuticals Inc Lifted by Analyst (OPNT)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/15/q2-2018-eps-estimates-for-opiant-pharmaceuticals-inc-lifted-by-analyst-opnt.html.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply